Edwards Lifesciences
EW
101.85
-2.03
-1.95%
Edwards Lifesciences
US · EW
#442 by market cap
Listed 1970
101.85
-2.03
-1.95%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Improving
7
■ Upgrades■ Downgrades
- 7 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: Baird moved from Hold to Buy on 2026-11-05.
Analyst consensus 21 analysts
Buy
Avg price target 116.05 +13.9%
Price target rangecurrent 101.85
Low105.00
Avg116.05
High125.00
Buy 95%
Hold 5%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-19 | Leerink Partners | -- | Buy | 116.00 |
| 2026-11-19 | RBC Capital | -- | Buy | 115.00 |
| 2026-11-16 | Wells Fargo | -- | Buy | 121.00 |
| 2026-11-11 | TD Cowen | -- | Buy | 121.00 |
| 2026-11-09 | BofA Securities | -- | Buy | -- |
| 2026-11-05 | TD Cowen | -- | Buy | 117.00 |
| 2026-11-05 | Wells Fargo | -- | Buy | 113.00 |
| 2026-11-05 | Bernstein | -- | Hold | 106.00 |
| 2026-11-05 | UBS | -- | Buy | 118.00 |
| 2026-11-05 | DBS | -- | Buy | 125.00 |
| 2026-11-05 | Mizuho Securities | -- | Buy | 120.00 |
| 2026-11-05 | Piper Sandler | -- | Buy | 115.00 |
| 2026-11-05 | BofA Securities | -- | Buy | -- |
| 2026-11-05 | Baird | -- | Buy | 116.00 |
| 2026-11-05 | Evercore | -- | Buy | 112.00 |
| 2026-11-05 | Stifel | -- | Buy | 120.00 |
| 2026-11-05 | Citi | -- | Buy | 117.00 |
| 2026-11-05 | Goldman Sachs | -- | Buy | 115.00 |
| 2026-11-05 | Leerink Partners | -- | Buy | 112.00 |
| 2026-11-05 | Barclays | -- | Buy | 120.00 |
| 2026-11-05 | RBC Capital | -- | Buy | 115.00 |
| 2026-11-05 | J.P. Morgan | -- | Buy | 120.00 |
| 2026-11-04 | Wells Fargo | -- | Buy | 113.00 |
| 2026-11-04 | Citi | -- | Buy | 117.00 |
| 2026-11-04 | Barclays | -- | Buy | 110.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-11-05 | Baird | Hold → Buy | 116.00 |
| 2026-11-03 | Truist Financial | Hold → Buy | 113.00 |
| 2026-07-28 | UBS | Hold → Buy | 110.00 |
| 2026-07-24 | Leerink Partners | Hold → Buy | 101.00 |
| 2026-04-01 | Wolfe Research | Hold → Buy | 92.00 |
| 2026-01-09 | TD Cowen | Hold → Buy | 97.00 |
| 2025-12-18 | J.P. Morgan | Hold → Buy | 100.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | After close | ±5.52% | +1.46% (in line) |
| 2026/Q2 | 2026-07-23 | After close | ±9.52% | -1.42% (in line) |
| 2026/Q1 | 2026-04-23 | After close | ±8.75% | +5.56% (in line) |
| 2025/Q4 | 2026-02-10 | After close | ±7.19% | +2.96% (in line) |
| 2025/Q3 | 2025-10-30 | After close | ±6.57% | -1.23% (in line) |
| 2025/Q2 | 2025-07-24 | After close | ±9.50% | +5.54% (in line) |
| 2025/Q1 | 2025-04-23 | After close | ±9.96% | +6.63% (in line) |
| 2024/Q4 | 2025-02-11 | After close | ±7.44% | +6.92% (in line) |
| 2024/Q3 | 2024-10-24 | After close | ±11.16% | -1.38% (in line) |
| 2024/Q2 | 2024-07-24 | After close | ±7.87% | -31.34% (beat) |
| 2024/Q1 | 2024-04-25 | After close | ±7.76% | -1.80% (in line) |
| 2023/Q4 | 2024-02-06 | After close | ±7.62% | -1.86% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Edwards Lifesciences discussion 0 comments